Lysosomal acid lipase deficiency – early diagnosis is the key

References

• Muntoni S, Wiebusch H, Jansen-Rust M, et al. Prevalence of cholesteryl ester storage disease. Arterioscler Thromb Vasc Biol. 2007;27(8):1866–1868. doi:10.1161/ATVBAHA.107.14663917634524
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Dana SE, Faust JR, Beaudet AL, Brown MS. Role of lysosomal acid lipase in the metabolism of plasma low density lipoprotein. Observations in cultured fibroblasts from a patient with cholesteryl ester storage disease. J Biol Chem. 1975;250(21):8487–8495.172501
   PubMed Web of Science ®Google Scholar
• Sloan HR, Fredrickson DS. Enzyme deficiency in cholesteryl ester storage idisease. J Clin Invest. 1972;51(7):1923–1926. doi:10.1172/JCI1069975032533
   PubMed Web of Science ®Google Scholar
• Beaudet AL, Ferry GD, Nichols BL Jr, Rosenberg HS. Cholesterol ester storage disease: clinical, biochemical, and pathological studies. J Pediatr. 1977;90(6):910–914.859064
   PubMed Web of Science ®Google Scholar
• Bernstein DL, Hulkova H, Bialer MG, Desnick RJ. Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013;58(6):1230–1243. doi:10.1016/j.jhep.2013.02.01423485521
   PubMed Web of Science ®Google Scholar
• Abramov A, Schorr S, Wolman M. Generalized xanthomatosis with calcified adrenals. AMA J Dis Child. 1956;91(3):282–286.13301142
   PubMedGoogle Scholar
• Jones SA, Valayannopoulos V, Schneider E, et al. Rapid progression and mortality of lysosomal acid lipase deficiency presenting in infants. Genet Med. 2016;18(5):452–458. doi:10.1038/gim.2015.10826312827
   PubMed Web of Science ®Google Scholar
• Jones SA, Rojas-Caro S, Quinn AG, et al. Survival in infants treated with sebelipase alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study. Orphanet J Rare Dis. 2017;12(1):017–0587. doi:10.1186/s13023-017-0587-3
   Web of Science ®Google Scholar
• Aslanidis C, Ries S, Fehringer P, Buchler C, Klima H, Schmitz G. Genetic and biochemical evidence that CESD and Wolman disease are distinguished by residual lysosomal acid lipase activity. Genomics. 1996;33(1):85–93. doi:10.1006/geno.1996.01628617513
   PubMed Web of Science ®Google Scholar
• Pagani F, Pariyarath R, Garcia R, et al. New lysosomal acid lipase gene mutants explain the phenotype of Wolman disease and cholesteryl ester storage disease. J Lipid Res. 1998;39(7):1382–1388.9684740
   PubMed Web of Science ®Google Scholar
• Wolman M, Sterk VV, Gatt S, Frenkel M. Primary familial xanthomatosis with involvement and calcification of the adrenals. Report of two more cases in siblings of a previously described infant. Pediatrics. 1961;28:742–757.14008104
   PubMed Web of Science ®Google Scholar
• Crocker AC, Vawter GF, Neuhauser EB, Rosowsky A. Wolman’s disease: three new patients with a recently described lipidosis. Pediatrics. 1965;35:627–640.14269714
   PubMed Web of Science ®Google Scholar
• Marshall WC, Ockenden BG, Fosbrooke AS, Cumings JN. Wolman’s disease. A rare lipidosis with adrenal calcification. Arch Dis Child. 1969;44(235):331–341.5785183
   PubMed Web of Science ®Google Scholar
• Zhang B, Porto AF. Cholesteryl ester storage disease: protean presentations of lysosomal acid lipase deficiency. J Pediatr Gastroenterol Nutr. 2013;56(6):682–685. doi:10.1097/MPG.0b013e31828b36ac23403440
   PubMed Web of Science ®Google Scholar
• Aigner E, Feldman A, Neureiter D, Datz C, Ratziu V, Paulweber B. Benefit of treatment with sebelipase-alfa in a 63-year-old patient with advanced liver and atherosclerotic disease due to lysosomal acid lipase deficiency (LAL-D). Am J Gastroenterol. 2018;113(3):443–445. doi:10.1038/ajg.2017.48629535442
   PubMed Web of Science ®Google Scholar
• Castro Narro GE, Gamboa Dominguez A, Consuelo Sanchez A, et al. Combined hepatocellular-cholangiocarcinoma in a patient with cirrhosis due to cholesteryl ester storage disease. Hepatology. 2018;29(10):30331.
   Google Scholar
• Canbay A, Muller MN, Philippou S, Gerken G, Tromm A. Cholesteryl ester storage disease: fatal outcome without causal therapy in a female patient with the preventable sequelae of progressive liver disease after many years of mild symptoms. Am J Case Rep. 2018;19:577–581. doi:10.12659/AJCR.90775529773783
   PubMed Web of Science ®Google Scholar
• Burton BK, Balwani M, Feillet F, et al. A phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency. N Engl J Med. 2015;373(11):1010–1020. doi:10.1056/NEJMoa150136526352813
   PubMed Web of Science ®Google Scholar
• Anderson RA, Rao N, Byrum RS, et al. In situ localization of the genetic locus encoding the lysosomal acid lipase/cholesteryl esterase (LIPA) deficient in Wolman disease to chromosome 10q23.2-q23.3. Genomics. 1993;15(1):245–247. doi:10.1006/geno.1993.10528432549
   PubMed Web of Science ®Google Scholar
• Koch G, Lalley PA, McAvoy M, Shows TB. Assignment of LIPA, associated with human acid lipase deficiency, to human chromosome 10 and comparative assignment to mouse chromosome 19. Somatic Cell Genet. 1981;7(3):345–358.7292252
   PubMedGoogle Scholar
• Carter A, Brackley SM, Gao J, Mann JP. The global prevalence and genetic spectrum of lysosomal acid lipase deficiency: a rare condition that mimics NAFLD. J Hepatol. 2019;70(1):142–150. doi:10.1016/j.jhep.2018.09.02830315827
   PubMed Web of Science ®Google Scholar
• Lohse P, Maas S, Elleder M, Kirk JM, Besley GT, Seidel D. Compound heterozygosity for a Wolman mutation is frequent among patients with cholesteryl ester storage disease. J Lipid Res. 2000;41(1):23–31.10627498
   PubMed Web of Science ®Google Scholar
• Burke JA, Schubert WK. Deficient activity of hepatic acid lipase in cholesterol ester storage disease. Science. 1972;176(4032):309–310.5019788
   PubMed Web of Science ®Google Scholar
• Stitziel NO, Fouchier SW, Sjouke B, et al. Exome sequencing and directed clinical phenotyping diagnose cholesterol ester storage disease presenting as autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2013;33(12):2909–2914. doi:10.1161/ATVBAHA.113.30242624072694
   PubMed Web of Science ®Google Scholar
• Scott SA, Liu B, Nazarenko I, et al. Frequency of the cholesteryl ester storage disease common LIPA E8SJM mutation (c.894G>A) in various racial and ethnic groups. Hepatology. 2013;58(3):958–965. doi:10.1002/hep.2632723424026
   PubMed Web of Science ®Google Scholar
• Tovoli F, Napoli L, Negrini G. et al., A relative deficiency of lysosomal acid lypase activity characterizes non-alcoholic fatty liver disease. Int J Mol Sci. 2017;18:6.
   Web of Science ®Google Scholar
• Patrick AD, Lake BD. Deficiency of an acid lipase in Wolman’s disease. Nature. 1969;222(5198):1067–1068.5787090
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM, Ishak KG, Rabin L, Hoeg JM. Cholesteryl ester storage disease: hepatopathology and effects of therapy with lovastatin. Hepatology. 1990;11(5):764–772.2347551
   PubMed Web of Science ®Google Scholar
• Hulkova H, Elleder M. Distinctive histopathological features that support a diagnosis of cholesterol ester storage disease in liver biopsy specimens. Histopathology. 2012;60(7):1107–1113. doi:10.1111/j.1365-2559.2011.04164.x22621222
   PubMed Web of Science ®Google Scholar
• Walenbergh SM, Shiri-Sverdlov R. Cholesterol is a significant risk factor for non-alcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol. 2015;9(11):1343–1346. doi:10.1586/17474124.2015.109238226395315
   PubMed Web of Science ®Google Scholar
• Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109(9):1125–1131. doi:10.1172/JCI1559311994399
   PubMed Web of Science ®Google Scholar
• Reiner Z, Guardamagna O, Nair D, et al. Lysosomal acid lipase deficiency–an under-recognized cause of dyslipidaemia and liver dysfunction. Atherosclerosis. 2014;235(1):21–30. doi:10.1016/j.atherosclerosis.2014.04.00324792990
   PubMed Web of Science ®Google Scholar
• Jeon T-I, Osborne TF. SREBPs: metabolic integrators in physiology and metabolism. Trends Endocrinol Metab. 2012;23(2):65–72. doi:10.1016/j.tem.2011.10.00422154484
   PubMed Web of Science ®Google Scholar
• Cummings MH, Watts GF, Umpleby AM, et al. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetologia. 1995;38(8):959–967.7589883
   PubMed Web of Science ®Google Scholar
• Bowden KL, Bilbey NJ, Bilawchuk LM, et al. Lysosomal acid lipase deficiency impairs regulation of ABCA1 gene and formation of high density lipoproteins in cholesteryl ester storage disease. J Biol Chem. 2011;286(35):30624–30635. doi:10.1074/jbc.M111.27438121757691
   PubMed Web of Science ®Google Scholar
• Ambler GK, Hoare M, Brais R, et al. Orthotopic liver transplantation in an adult with cholesterol ester storage disease. JIMD Rep. 2012;8:41–46. doi:10.1007/8904_2012_15523430518
   PubMedGoogle Scholar
• Elleder M, Chlumská A, Hyánek J, et al. Subclinical course of cholesteryl ester storage disease in an adult with hypercholesterolemia, accelerated atherosclerosis, and liver cancer. J Hepatol. 2000;32(3):528–534.10735626
   PubMed Web of Science ®Google Scholar
• Vom Dahl S, Harzer K, Rolfs A, et al. Hepatosplenomegalic lipidosis: what unless Gaucher? Adult cholesteryl ester storage disease (CESD) with anemia, mesenteric lipodystrophy, increased plasma chitotriosidase activity and a homozygous lysosomal acid lipase -1 exon 8 splice junction mutation. J Hepatol. 1999;31(4):741–746.10551400
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357. doi:10.1002/hep.2936728714183
   PubMed Web of Science ®Google Scholar
• Marchesini, G, Day, CP, Dufour, JF, et al.. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402.27062661
   PubMed Web of Science ®Google Scholar
• Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415–1428. doi:10.1016/S0140-6736(05)66378-715836891
   PubMed Web of Science ®Google Scholar
• Hamilton J, Jones I, Srivastava R, Galloway P. A new method for the measurement of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2. Clin Chim Acta. 2012;413(15–16):1207–1210. doi:10.1016/j.cca.2012.03.01922483793
   PubMed Web of Science ®Google Scholar
• Schiff L, Schubert WK, McAdams AJ, Spiegel EL, O’Donnell JF. Hepatic cholesterol ester storage disease, a familial disorder. I. Clinical aspects. Am J Med. 1968;44(4):538–546.5642714
   PubMed Web of Science ®Google Scholar
• Zandanell S, Primavesi F, Aigner E. Hepatosteatosis from lysosomal acid lipase deficiency. J Gastrointest Surg. 2018;6(10):018–3906.
   Google Scholar
• Vom Dahl S, Mengel E. Lysosomal storage diseases as differential diagnosis of hepatosplenomegaly. Best Pract Res Clin Gastroenterol. 2010;24(5):619–628. doi:10.1016/j.bpg.2010.09.00120955964
   PubMed Web of Science ®Google Scholar
• Goldberg IJ. Diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab. 2001;86(3):965–971. doi:10.1210/jcem.86.3.730411238470
   PubMed Web of Science ®Google Scholar
• Chora JR, Alves AC, Medeiros AM, et al. Lysosomal acid lipase deficiency: a hidden disease among cohorts of familial hypercholesterolemia? J Clin Lipidol. 2017;11(2):477–484. doi:10.1016/j.jacl.2016.11.00228502505
   PubMed Web of Science ®Google Scholar
• Pullinger CR, Stock EO, Movsesyan I, et al. Identification and metabolic profiling of patients with lysosomal acid lipase deficiency. J Clin Lipidol. 2015;9(5):716–726. doi:10.1016/j.jacl.2015.07.00826350820
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500–1509. doi:10.1056/NEJMoa150085825773607
   PubMed Web of Science ®Google Scholar
• Boot RG, Renkema GH, Strijland A, van Zonneveld AJ, Aerts JM. Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages. J Biol Chem. 1995;270(44):26252–26256.7592832
   PubMed Web of Science ®Google Scholar
• Anderson G, Smith VV, Malone M, Sebire NJ. Blood film examination for vacuolated lymphocytes in the diagnosis of metabolic disorders; retrospective experience of more than 2,500 cases from a single centre. J Clin Pathol. 2005;58(12):1305–1310. doi:10.1136/jcp.2005.02704516311352
   PubMed Web of Science ®Google Scholar
• Lake BD. Histochemical detection of the enzyme deficiency in blood films in Wolman’s disease. J Clin Pathol. 1971;24(7):617–620.5118828
   PubMed Web of Science ®Google Scholar
• Civallero G, De Mari J, Bittar C, Burin M, Giugliani R. Extended use of a selective inhibitor of acid lipase for the diagnosis of Wolman disease and cholesteryl ester storage disease. Gene. 2014;539(1):154–156. doi:10.1016/j.gene.2014.02.00324508470
   PubMed Web of Science ®Google Scholar
• Rassoul F, Richter V, Lohse P, Naumann A, Purschwitz K, Keller E. Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther. 2001;39(5):199–204.11380065
   PubMed Web of Science ®Google Scholar
• Tadiboyina VT, Liu DM, Miskie BA, Wang J, Hegele RA. Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease. Lipids Health Dis. 2005;4(26):4–26. doi:10.1186/1476-511X-4-415705191
   PubMedGoogle Scholar
• Gasche C, Aslanidis C, Kain R, et al. A novel variant of lysosomal acid lipase in cholesteryl ester storage disease associated with mild phenotype and improvement on lovastatin. J Hepatol. 1997;27(4):744–750.9365051
   PubMed Web of Science ®Google Scholar
• Levy R, Ostlund RE Jr., Schonfeld G, Wong P, Semenkovich CF. Cholesteryl ester storage disease: complex molecular effects of chronic lovastatin therapy. J Lipid Res. 1992;33(7):1005–1015.1431581
   PubMed Web of Science ®Google Scholar
• McCoy E, Yokoyama S. Treatment of cholesteryl ester storage disease with combined cholestyramine and lovastatin. Ann N Y Acad Sci. 1991;623:453–454.2042867
   PubMed Web of Science ®Google Scholar
• Leone L, Ippoliti PF, Antonicelli R, Balli F, Gridelli B. Treatment and liver transplantation for cholesterol ester storage disease. J Pediatr. 1995;127(3):509–510.7658290
   PubMed Web of Science ®Google Scholar
• Ma PT, Gil G, Südhof TC, Bilheimer DW, Goldstein JL, Brown MS. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci U S A. 1986;83(21):8370–8374.3464957
   PubMed Web of Science ®Google Scholar
• Stein J, Garty BZ, Dror Y, Fenig E, Zeigler M, Yaniv I. Successful treatment of Wolman disease by unrelated umbilical cord blood transplantation. Eur J Pediatr. 2007;166(7):663–666. doi:10.1007/s00431-006-0298-617033804
   PubMed Web of Science ®Google Scholar
• Tolar J, Petryk A, Khan K, et al. Long-term metabolic, endocrine, and neuropsychological outcome of hematopoietic cell transplantation for Wolman disease. Bone Marrow Transplant. 2009;43(1):21–27. doi:10.1038/bmt.2008.27318776925
   PubMed Web of Science ®Google Scholar
• Krivit W, Peters C, Dusenbery K, et al. Wolman disease successfully treated by bone marrow transplantation. Bone Marrow Transplant. 2000;26(5):567–570. doi:10.1038/sj.bmt.170255711019848
   PubMed Web of Science ®Google Scholar
• Gramatges MM, Dvorak CC, Regula DP, Enns GM, Weinberg K, Agarwal R. Pathological evidence of Wolman’s disease following hematopoietic stem cell transplantation despite correction of lysosomal acid lipase activity. Bone Marrow Transplant. 2009;44(7):449–450. doi:10.1038/bmt.2009.5719308038
   PubMed Web of Science ®Google Scholar
• Yanir A, Allatif MA, Weintraub M, Stepensky P. Unfavorable outcome of hematopoietic stem cell transplantation in two siblings with Wolman disease due to graft failure and hepatic complications. Mol Genet Metab. 2013;109(2):224–226. doi:10.1016/j.ymgme.2013.03.00723583223
   PubMed Web of Science ®Google Scholar
• Bernstein DL, Lobritto S, Iuga A, et al. Lysosomal acid lipase deficiency allograft recurrence and liver failure- clinical outcomes of 18 liver transplantation patients. Mol Genet Metab. 2018;124(1):11–19. doi:10.1016/j.ymgme.2018.03.01029655841
   PubMed Web of Science ®Google Scholar
• Balwani M, Breen C, Enns GM, et al. Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage disease. Hepatology. 2013;58(3):950–957. doi:10.1002/hep.2628923348766
   PubMed Web of Science ®Google Scholar
• Valayannopoulos V, Malinova V, Honzik T, et al. Sebelipase alfa over 52 weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency. J Hepatol. 2014;61(5):1135–1142. doi:10.1016/j.jhep.2014.06.02224993530
   PubMed Web of Science ®Google Scholar